Ann: Q4 FY24 Investor Presentation, page-16

Just IMO, I reckon this coming flu season the company will see $1M+ in product sales across the two products. Evidenced by the $700k+ in the December sales from last year. I cant recall seeing anywhere, but I am wondering if Viradx is or will be available to the greater reach with LDX? Not sure if its available in AUS/NZ or the European markets at all? We could see substantial revenue if it was to be, if not.

Services continues to maintain ( and has done relative to its IPO) around $10MUSD in services revenue. This could increase with further customers coming on board which they indicated there were another 2.

I am curious who the other major Hologic style players they are in discussions with are. What was that for? Other services work similar to Hologic or were they talking about expansion of Febridx channels?